Product Description
TQ-B211 is being developed by Sino Biopharmaceutical for the treatment of patients with HER2-positive Metastatic Breast Cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04385563?term=TQ-B211&draw=2&rank=1)
Mechanisms of Action: ERBB2 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sino Biopharmaceutical
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TQB211-III-01 | P3 |
Unknown status |
Breast Cancer |
2021-02-01 |
43% |